文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

孤儿核受体转录因子作为药物靶点。

Orphan nuclear receptor transcription factors as drug targets.

作者信息

Safe Stephen, Oany Arafat R, Tsui Wai Ning, Lee Miok, Srivastava Vinod, Upadhyay Srijana, Hailemariam Amanuel, Farkas Evan, Kakwan Sarah, Kearns Caitrina, Sivaram Gargi

机构信息

Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA.

Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.

出版信息

Transcription. 2025 Apr-Jun;16(2-3):224-260. doi: 10.1080/21541264.2025.2521766. Epub 2025 Jul 11.


DOI:10.1080/21541264.2025.2521766
PMID:40646688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12263127/
Abstract

The nuclear receptor (NR) superfamily of ligand-activated receptors plays a key role in maintaining cellular homeostasis and in pathophysiology. NRs can be subdivided into functional activities structural similarity and the existence of endogenous ligands. Most NRs are classified as those that are adopted orphan or orphan receptors which have only possible ligands or no identified endogenous ligands, respectively. In this review, the activities of the complete orphan receptor sub-family of transcription factors have been reviewed with a focus on the effects of possible endogenous (biochemicals), natural product-derived and synthetic ligands. Despite their lack of a bona-fide ligand, the orphan receptors bind structurally diverse compounds that exhibit tissue-specific agonist, antagonist and inverse agonist activities with potential for future development as clinical therapeutics for the treatment of multiple diseases.

摘要

配体激活受体的核受体(NR)超家族在维持细胞稳态和病理生理学中起关键作用。NR可根据功能活性、结构相似性和内源性配体的存在进行细分。大多数NR被分类为采用型孤儿受体或孤儿受体,分别只有可能的配体或未鉴定出内源性配体。在本综述中,对转录因子的完整孤儿受体亚家族的活性进行了综述,重点关注可能的内源性(生物化学物质)、天然产物衍生和合成配体的作用。尽管缺乏真正的配体,但孤儿受体能结合结构多样的化合物,这些化合物表现出组织特异性激动剂、拮抗剂和反向激动剂活性,具有作为多种疾病临床治疗药物未来开发的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/060725f2235b/KTRN_A_2521766_F0019_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/759ce77b0c5f/KTRN_A_2521766_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/d6e74391c40f/KTRN_A_2521766_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/8a9f72483868/KTRN_A_2521766_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/144244f2aeaa/KTRN_A_2521766_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/85853527dcd4/KTRN_A_2521766_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/f62d604c351c/KTRN_A_2521766_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/8e2e311d6776/KTRN_A_2521766_F0007_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/701d120c5def/KTRN_A_2521766_F0008_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/9c568032b632/KTRN_A_2521766_F0009_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/46192880fbfc/KTRN_A_2521766_F0010_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/4d52e5974613/KTRN_A_2521766_F0011_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/1fae13755084/KTRN_A_2521766_F0012_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/e78bf5fc5f55/KTRN_A_2521766_F0013_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/23c20e28ab0a/KTRN_A_2521766_F0014_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/a4d84b9927f6/KTRN_A_2521766_F0015_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/a18095cf4667/KTRN_A_2521766_F0016_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/9658a792ac47/KTRN_A_2521766_F0017_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/f0a18349c222/KTRN_A_2521766_F0018_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/060725f2235b/KTRN_A_2521766_F0019_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/759ce77b0c5f/KTRN_A_2521766_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/d6e74391c40f/KTRN_A_2521766_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/8a9f72483868/KTRN_A_2521766_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/144244f2aeaa/KTRN_A_2521766_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/85853527dcd4/KTRN_A_2521766_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/f62d604c351c/KTRN_A_2521766_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/8e2e311d6776/KTRN_A_2521766_F0007_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/701d120c5def/KTRN_A_2521766_F0008_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/9c568032b632/KTRN_A_2521766_F0009_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/46192880fbfc/KTRN_A_2521766_F0010_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/4d52e5974613/KTRN_A_2521766_F0011_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/1fae13755084/KTRN_A_2521766_F0012_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/e78bf5fc5f55/KTRN_A_2521766_F0013_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/23c20e28ab0a/KTRN_A_2521766_F0014_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/a4d84b9927f6/KTRN_A_2521766_F0015_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/a18095cf4667/KTRN_A_2521766_F0016_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/9658a792ac47/KTRN_A_2521766_F0017_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/f0a18349c222/KTRN_A_2521766_F0018_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9740/12263127/060725f2235b/KTRN_A_2521766_F0019_B.jpg

相似文献

[1]
Orphan nuclear receptor transcription factors as drug targets.

Transcription. 2025

[2]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[3]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[4]
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.

Health Technol Assess. 2006-7

[5]
Autoimmune Lymphoproliferative Syndrome

1993

[6]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

[7]
Melatonin and Its Metabolites Can Serve as Agonists on the Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor Gamma.

Int J Mol Sci. 2023-10-23

[8]
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].

Zhonghua Jie He He Hu Xi Za Zhi. 2025-3-12

[9]
Short-Term Memory Impairment

2025-1

[10]
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Health Technol Assess. 2001

本文引用的文献

[1]
Dual nuclear receptor 4A1 (NR4A1/NR4A2) ligands inhibit glioblastoma growth and target TWIST1.

Mol Pharmacol. 2025-2

[2]
Activation of Genes by Nuclear Receptor/Specificity Protein (Sp) Interactions in Cancer.

Cancers (Basel). 2025-1-17

[3]
Orphan nuclear receptor NR2E3 is a new molecular vulnerability in solid tumors by activating p53.

Cell Death Dis. 2025-1-14

[4]
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.

Cancer Lett. 2024-8-10

[5]
Targeting Nr2e3 to Modulate Tet2 Expression: Therapeutic Potential for Depression Treatment.

Adv Sci (Weinh). 2024-8

[6]
Roles of Nuclear Orphan Receptors TR2 and TR4 during Hematopoiesis.

Genes (Basel). 2024-4-27

[7]
The Loss of an Orphan Nuclear Receptor NR2E3 Augments Wnt/β-catenin Signaling via Epigenetic Dysregulation that Enhances Sp1-β catenin-p300 Interactions in Hepatocellular Carcinoma.

Adv Sci (Weinh). 2024-8

[8]
Bis-Indole Derivatives as Dual Nuclear Receptor 4A1 (NR4A1) and NR4A2 Ligands.

Biomolecules. 2024-2-27

[9]
Screening of Chelidonium majus isoquinoline alkaloids reveals berberine and chelidonine as selective ligands for the nuclear receptors RORβ and HNF4α, respectively.

Arch Pharm (Weinheim). 2024-7

[10]
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.

J Exp Med. 2024-3-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索